Company news
Intensity Therapeutics, Inc. news in 2022
Intensity Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)
December 7, 2022
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society...
November 17, 2022
Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers
November 10, 2022
Intensity Therapeutics, The Ottawa Hospital and Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers
November 9, 2022
Decks in 2022
- CTOS Annual Meeting 2022
Conference · 17 slides · Nov 18, 2022
- IPO Roadshow (October 2022)
IPO roadshow · 21 slides · October 2022
- IPO Roadshow (September 2022)
IPO roadshow · 28 slides · Sep 20, 2022
- IPO Roadshow (April 2022)
IPO roadshow · 23 slides · Apr 20, 2022
- Investor Presentation (March 2022)
Investor deck · 21 slides · Mar 15, 2022